Difficulty: Medium
Average Score: 72%
Practice
In Langerhans cell histiocytosis (LCH), all the following manifestations are at high risk of mortality in patients EXCEPT
Correct answer
C
Rationale
In Langerhans cell histiocytosis (LCH), manifestations in various organs can lead to significant morbidity and mortality. The correct answer, option C (lung), is not typically associated with a high risk of mortality in LCH.
The lung involvement in LCH can lead to symptoms such as cough, dyspnea, and interstitial lung disease, but mortality rates directly attributed to lung involvement are lower compared to other organ systems like the liver, spleen, and hematopoietic system.
Liver involvement (option A) in LCH can result in liver failure and associated complications, leading to a higher risk of mortality. Spleen involvement (option B) can cause hypersplenism and thrombocytopenia, which can be life-threatening. Hematopoietic system involvement (option D) can lead to bone marrow failure and severe cytopenias, increasing the risk of mortality.
In an educational context, understanding the organ-specific risks associated with LCH is crucial for healthcare providers managing pediatric patients with this condition. It highlights the importance of early recognition, multidisciplinary management, and close monitoring to prevent and address potential life-threatening complications.
The lung involvement in LCH can lead to symptoms such as cough, dyspnea, and interstitial lung disease, but mortality rates directly attributed to lung involvement are lower compared to other organ systems like the liver, spleen, and hematopoietic system.
Liver involvement (option A) in LCH can result in liver failure and associated complications, leading to a higher risk of mortality. Spleen involvement (option B) can cause hypersplenism and thrombocytopenia, which can be life-threatening. Hematopoietic system involvement (option D) can lead to bone marrow failure and severe cytopenias, increasing the risk of mortality.
In an educational context, understanding the organ-specific risks associated with LCH is crucial for healthcare providers managing pediatric patients with this condition. It highlights the importance of early recognition, multidisciplinary management, and close monitoring to prevent and address potential life-threatening complications.